FDA advisory panel calls for suicide warnings over new antidepressantssBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7435.303-a (Published 05 February 2004) Cite this as: BMJ 2004;328:303
- Ray Moynihan
In a surprise move on 2 February, a panel of scientific advisers of the US Food and Drug Administration urged the agency to warn that new anti-depressants may increase the risk of suicidal thinking or behaviour among children and teenagers.
During a 10 hour hearing, experts weighed the official presentations of uncertain scientific data against powerful emotional testimony from dozens of families whose children have killed themselves or others after …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial